Matches in Nanopublications for { ?s ?p "[Although the effect of new drugs such as poly(ADP-ribose) polymerase inhibitors are being investigated in ovarian cancer, there is still a need to develop targeted therapies-especially to tackle mutations in PI3 K pathway, RAS pathway and TP53.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 8 of
8
with 100 items per page.
- assertion description "[Although the effect of new drugs such as poly(ADP-ribose) polymerase inhibitors are being investigated in ovarian cancer, there is still a need to develop targeted therapies-especially to tackle mutations in PI3 K pathway, RAS pathway and TP53.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Although the effect of new drugs such as poly(ADP-ribose) polymerase inhibitors are being investigated in ovarian cancer, there is still a need to develop targeted therapies-especially to tackle mutations in PI3 K pathway, RAS pathway and TP53.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Although the effect of new drugs such as poly(ADP-ribose) polymerase inhibitors are being investigated in ovarian cancer, there is still a need to develop targeted therapies-especially to tackle mutations in PI3 K pathway, RAS pathway and TP53.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Although the effect of new drugs such as poly(ADP-ribose) polymerase inhibitors are being investigated in ovarian cancer, there is still a need to develop targeted therapies-especially to tackle mutations in PI3 K pathway, RAS pathway and TP53.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1244677.RARCUxd0bhy9vw_cD10lo_LwJfBiXQYrNm03ryA359pw8130_assertion description "[Although the effect of new drugs such as poly(ADP-ribose) polymerase inhibitors are being investigated in ovarian cancer, there is still a need to develop targeted therapies-especially to tackle mutations in PI3 K pathway, RAS pathway and TP53.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1244677.RARCUxd0bhy9vw_cD10lo_LwJfBiXQYrNm03ryA359pw8130_provenance.
- NP1244675.RAt_xJAJfhzoYZgYDF5cZBMjehHcm8LmAP8rv4dch_4L4130_assertion description "[Although the effect of new drugs such as poly(ADP-ribose) polymerase inhibitors are being investigated in ovarian cancer, there is still a need to develop targeted therapies-especially to tackle mutations in PI3 K pathway, RAS pathway and TP53.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1244675.RAt_xJAJfhzoYZgYDF5cZBMjehHcm8LmAP8rv4dch_4L4130_provenance.
- NP1244676.RAI8fEAaqSCUuQ6ufllTkuBygdlPn4KUeGDZf-w2kKWRE130_assertion description "[Although the effect of new drugs such as poly(ADP-ribose) polymerase inhibitors are being investigated in ovarian cancer, there is still a need to develop targeted therapies-especially to tackle mutations in PI3 K pathway, RAS pathway and TP53.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1244676.RAI8fEAaqSCUuQ6ufllTkuBygdlPn4KUeGDZf-w2kKWRE130_provenance.
- NP1244678.RA3aIHmS3w05d8Pg5y9TI5t_ugTJRJFgnsgOyYhXvLtkI130_assertion description "[Although the effect of new drugs such as poly(ADP-ribose) polymerase inhibitors are being investigated in ovarian cancer, there is still a need to develop targeted therapies-especially to tackle mutations in PI3 K pathway, RAS pathway and TP53.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1244678.RA3aIHmS3w05d8Pg5y9TI5t_ugTJRJFgnsgOyYhXvLtkI130_provenance.